Novartis Can't Rush Appeal In Elidel FCA Suit, Judge Says

Law360, New York (August 27, 2013, 1:14 PM EDT) -- A Pennsylvania federal judge on Friday denied Novartis Pharmaceuticals Corp.’s request to file an interlocutory appeal on part of her decision trimming down a whistleblower suit alleging the drugmaker defrauded government health care programs by promoting off-label uses of eczema treatment Elidel.

U.S. District Judge Gene E.K. Pratter denied Novartis’ motion to certify a portion of her June 13 decision — in which she declined to dismiss outright the long-running suit from qui tam relator Donald Galmines but stripped the anti-kickback claims and certain state False Claims...
To view the full article, register now.